[Porphyria cutanea tara]

Area of Science:

• Biochemistry
• Dermatology
• Genetics

Background:

• Porphyria cutanea tarda (PCT) is the most prevalent porphyria globally, affecting approximately 40 individuals per million annually.
• It stems from the inhibition of uroporphyrinogen decarboxylase (UROD), often due to UROD gene mutations.
• Environmental factors and co-existing conditions significantly contribute to PCT onset.

Purpose of the Study:

• To detail the prevalence, causes, and clinical manifestations of Porphyria cutanea tarda.
• To identify key risk factors and triggers associated with PCT development.
• To outline current therapeutic strategies for managing PCT.

Main Methods:

• Literature review of epidemiological data on PCT prevalence.
• Analysis of genetic and environmental factors contributing to UROD inhibition.
• Compilation of clinical signs, symptoms, and treatment protocols for PCT.

Main Results:

• PCT diagnosis rates are around 40 new cases per million people yearly.
• Hereditary UROD gene mutations and acquired factors like alcohol, iron overload, and hepatitis C are primary causes.
• Clinical presentation includes skin fragility, blisters, erosions, hyperpigmentation, and sclerodermoid plaques.

Conclusions:

• PCT is a common porphyria influenced by genetic and environmental factors.
• Early identification of risk factors and prompt treatment are crucial for managing PCT.
• Therapeutic approaches involve sun protection, risk factor avoidance, phlebotomy, and chloroquine administration.